Cargando…

Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study

Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, leptin, ghrelin, and substance P were meas...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyung Soon, Won, Hye Sung, An, Ho Jung, Cho, Sung Shim, Kim, Hyun Ho, Sun, Der Sheng, Ko, Yoon Ho, Shim, Byoung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897939/
https://www.ncbi.nlm.nih.gov/pubmed/33369184
http://dx.doi.org/10.1002/cam4.3693
_version_ 1783653768401780736
author Park, Hyung Soon
Won, Hye Sung
An, Ho Jung
Cho, Sung Shim
Kim, Hyun Ho
Sun, Der Sheng
Ko, Yoon Ho
Shim, Byoung Yong
author_facet Park, Hyung Soon
Won, Hye Sung
An, Ho Jung
Cho, Sung Shim
Kim, Hyun Ho
Sun, Der Sheng
Ko, Yoon Ho
Shim, Byoung Yong
author_sort Park, Hyung Soon
collection PubMed
description Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, leptin, ghrelin, and substance P were measured at baseline, day 3, and day 14 during the first cycle of chemotherapy. Nausea and vomiting were measured each day for the first 4 days of the first cycle of chemotherapy. Eighty‐two patients were enrolled. Colorectal cancer (61%) and gastric cancer (35.4%) were common cancer types. All patients received moderate emetic risk chemotherapy. Forty‐five (54.9%) patients had nausea, and 15 (18.3%) patients experienced vomiting. In univariate analysis, a higher level of baseline substance P, which is a target of NK1‐RA (Neurokinin 1 receptor antagonist), was a significant predictive marker for chemotherapy‐induced nausea [odds ratio (OR): 2.6, 95% confidence interval (CI): 1.02–6.62, p = 0.046]. Regarding chemotherapy‐induced vomiting, patients with higher levels of substance P had a greater chance of vomiting [OR: 1.72, 95% CI: 0.49–5.99, p = 0.395] than those with lower levels of substance P. In patients receiving moderate emetic risk chemotherapy, active antiemetics, including NK1‐RA, could be considered for those with high levels of substance P.
format Online
Article
Text
id pubmed-7897939
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78979392021-02-23 Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study Park, Hyung Soon Won, Hye Sung An, Ho Jung Cho, Sung Shim Kim, Hyun Ho Sun, Der Sheng Ko, Yoon Ho Shim, Byoung Yong Cancer Med Clinical Cancer Research Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, leptin, ghrelin, and substance P were measured at baseline, day 3, and day 14 during the first cycle of chemotherapy. Nausea and vomiting were measured each day for the first 4 days of the first cycle of chemotherapy. Eighty‐two patients were enrolled. Colorectal cancer (61%) and gastric cancer (35.4%) were common cancer types. All patients received moderate emetic risk chemotherapy. Forty‐five (54.9%) patients had nausea, and 15 (18.3%) patients experienced vomiting. In univariate analysis, a higher level of baseline substance P, which is a target of NK1‐RA (Neurokinin 1 receptor antagonist), was a significant predictive marker for chemotherapy‐induced nausea [odds ratio (OR): 2.6, 95% confidence interval (CI): 1.02–6.62, p = 0.046]. Regarding chemotherapy‐induced vomiting, patients with higher levels of substance P had a greater chance of vomiting [OR: 1.72, 95% CI: 0.49–5.99, p = 0.395] than those with lower levels of substance P. In patients receiving moderate emetic risk chemotherapy, active antiemetics, including NK1‐RA, could be considered for those with high levels of substance P. John Wiley and Sons Inc. 2020-12-27 /pmc/articles/PMC7897939/ /pubmed/33369184 http://dx.doi.org/10.1002/cam4.3693 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Park, Hyung Soon
Won, Hye Sung
An, Ho Jung
Cho, Sung Shim
Kim, Hyun Ho
Sun, Der Sheng
Ko, Yoon Ho
Shim, Byoung Yong
Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
title Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
title_full Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
title_fullStr Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
title_full_unstemmed Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
title_short Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study
title_sort elevated serum substance p level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: a prospective cohort study
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897939/
https://www.ncbi.nlm.nih.gov/pubmed/33369184
http://dx.doi.org/10.1002/cam4.3693
work_keys_str_mv AT parkhyungsoon elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT wonhyesung elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT anhojung elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT chosungshim elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT kimhyunho elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT sundersheng elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT koyoonho elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy
AT shimbyoungyong elevatedserumsubstanceplevelasapredictivemarkerformoderatelyemetogenicchemotherapyinducednauseaandvomitingaprospectivecohortstudy